**Press Release**

**IB Communications**

exmoor@ibcomms.agency

**eXmoor Pharma and Signadori Bio launch partnership to develop next-generation monocyte-based cell therapy for solid tumours**

**Bristol, UK and Paris, France —  17 June 2025:** [eXmoor Pharma](https://tracking.vuelio.co.uk/tracking/click?d=Nm0lZOrqvykaohfVaU3cRKxuQvjBg8Zhgl44dFLac3VCJgBgKTodA0VCDMDL_85gZ_oETsVZdQmnuzI0IS-QS8QcXWgiYYgJYViBlTpGz8TZ5DYIr2DE5zaZ_f96bQDA6mp1yEAaZsL0YokpX4kOVsY1), the integrated cell and gene therapy CDMO with embedded consultancy expertise, and [Signadori Bio](https://tracking.vuelio.co.uk/tracking/click?d=Nm0lZOrqvykaohfVaU3cREaec1vhpR4K7g9kr1OPV7xMpZqioF_F5io-GWXKldZU36Ewodtz1vzc5LR_RbLuZh48ZoZjWLKCHjSqX3THCwdDasgRe-YOwVTRpvo0g0OI6IGOOEmUcDOOkmuM0kJTdDs1), a French biotechnology company developing next-generation cancer therapies, today announced a new collaboration to accelerate the development of gene-modified monocyte-derived macrophage cell therapy targeting solid tumours.

Signadori Bio, a Sofinnova Partners-backed spin-out, is advancing a promising gene-modified monocyte therapy platform aimed at overcoming the challenges of treating solid cancers, developed at the Gustave Roussy Institute, one of the world’s leading oncology centres.

Under the agreement, eXmoor Pharma will undertake a comprehensive technology translation and development programme at its Cell & Gene Therapy Centre, supporting Signadori Bio in the critical transition from discovery through to GMP-compliant manufacturing of their lead candidate. eXmoor will also provide an interim Head of CMC to integrate into Signadori Bio’s leadership team and support a structured programme of technology translation, process development and CMC planning.

This collaborative approach is designed to guide the therapy through key development milestones, with a focus on progressing the lead candidate toward GMP-compliant manufacturing and readiness for first-in-human clinical trials.

The partners will operate under a shared decision-making framework, aligning scientific, technical and commercial planning with Signadori Bio’s investment trajectory. The programme is set to transition into full process development with a long-term view toward GMP manufacturing, leveraging eXmoor’s GMP manufacturing capabilities.

**Angela Osborne, CEO of eXmoor Pharma,** commented:

“We are delighted to partner with Signadori Bio on such a promising and sophisticated cell therapy programme. Their approach to targeting solid tumours with gene-modified monocytes is innovative and well-grounded in translational science. At eXmoor, we are committed to supporting cell and gene therapy pioneers through the complex journey from discovery to clinical impact. This collaboration reflects our shared belief in the potential of advanced therapies to deliver meaningful outcomes for patients.”

**Matthieu Coutet, CEO of Signadori Bio and Partner at Sofinnova Partners,** said:

“Partnering with eXmoor is a decisive step in our mission to bring next-generation monocyte-based therapies to patients with solid tumours. Their deep expertise in early-stage process development and GMP translation is exactly what we need at this critical inflection point. I’m also very pleased to welcome Evelien Stalmeijer as interim Head of CMC. Her leadership and experience will be key as we accelerate our path toward the clinic. We’re excited to work hand-in-hand with a team that understands the complexity and urgency of advancing pioneering science into impactful therapies.”

**About eXmoor Pharma**

eXmoor Pharma is the only integrated cell and gene therapy CDMO with over 20 years of consultancy expertise embedded at every stage of development. From early-phase strategy and process development to GMP manufacturing and commercialisation, eXmoor supports clients with deep technical knowledge, regulatory insight and flexible manufacturing solutions. With a purpose-built facility in Bristol, UK, and over 170 clients globally, eXmoor is a trusted partner for cell and gene therapy innovators looking to scale their therapies safely and efficiently.

**About Signadori Bio**

Signadori Bio is a preclinical-stage biopharmaceutical company developing an innovative monocyte-based cell therapy platform to treat solid tumours. Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, and based on research conducted at Gustave Roussy, Signadori’s approach aims to overcome the challenges of the tumour microenvironment by harnessing the immune potential of gene-modified monocytes. Signadori is based in Paris and backed by Sofinnova Partners.